State‐of‐the‐Art Clinical Article: Pharmacokinetic/Pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and Men
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Investigations over the past 20 years have demonstrated that antibacterials can vary markedly in the time course of antimicrobial activity. These differences in pharmacodynamic activity have implications for optimal dosage regimens. The results of more recent studies suggest that the magnitude of the pharmacokinetic/pharmacodynamic parameters required for efficacy are relatively similar in animal infection models and in human infections. However, there is still much to learn. Additional studies are needed to further correlate pharmacokinetic/pharmacodynamic parameters for many antibacterials with therapeutic efficacy in a variety of animal infection models and in human infections. The potential value of using pharmacokinetic/pharmacodynamic parameters as guides for establishing optimal dosing regimens for new and old drugs and for new emerging pathogens and resistant organisms, for setting susceptibility breakpoints, and for reducing the cost of drug development should make the continuing search for the therapeutic rationale of antibacterial dosing of mice and men worthwhile.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Moore, R. D., Lietman, P. S., & Smith, C. R. (1987) · Journal of Infectious Diseases · doi:10.1093/infdis/155.1.93 · Cited by 1,139 · cited 1×
“However, the opposite was observed in the major clinical trials correlating pharmacokinetic/pharmacodynamic parameters with the therapeutic efficacy of aminoglycosides [56].”
Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients
Forrest, A., Nix, D. E., Ballow, C. H., Goss, T. F., Birmingham, M. C., & Schentag, J. J. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.5.1073 · Cited by 1,101 · cited 2×
“[52] found that a 24-hour AUC/MIC value of > 125 was associated with satisfactory outcome for seriously ill patients treated with intravenous ciprofloxacin.”
Pallares, R., Liñares, J., Vadillo, M., Cabellos, C., Manresa, F., Viladrich, P. F., Martin, R., & Gudiol, F. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508243330802 · Cited by 773
Correlation of Antimicrobial Pharmacokinetic Parameters with Therapeutic Efficacy in an Animal Model
Vogelman, B., Gudmundsson, S., Leggett, J., Turnidge, J., Ebert, S., & Craig, W. A. (1988) · The Journal of Infectious Diseases · doi:10.1093/infdis/158.4.831 · Cited by 720 · cited 3×
“need to exceed the MIC for 100% of the dosing interval to exert a significant antibacterial effect [25-27, 36].”
Self-citationCraig, W. A. (1995) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/0732-8893(95)00053-d · Cited by 618 · cited 5×
“Several investigators have used multiple dosage regimens in animal infection models to correlate specific pharmacokinetic/pharmacodynamic parameters with the efficacy of various antibacterials against both gram-positive and gram-negative bacilli [9, 25-31].”
InfluentialSelf-citationBlaser, J., Stone, B. B., Groner, M. C., & Zinner, S. H. (1987) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.31.7.1054 · Cited by 481
Pharmacokinetics and pharmacodynamics of antibiotics in otitis media
CRAIG, W. A., & ANDES, D. (1996) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-199603000-00015 · Cited by 435 · cited 3×
“pneumoniae and Haemophilus influenzae in patients with otitis media [38, 43].”
InfluentialSelf-citationDrusano, G. L., Johnson, D. E., Rosen, M., & Standiford, H. C. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.3.483 · Cited by 426 · cited 2×
“there is a significant risk of the emergence of resistant subpopulations [29].”
Leggett, J. E., Fantin, B., Ebert, S., Totsuka, K., Vogelman, B., Calame, W., Mattie, H., & Craig, W. A. (1989) · Journal of Infectious Diseases · doi:10.1093/infdis/159.2.281 · Cited by 354
Self-citationKinetics of antimicrobial activity
Vogelman, B., & Craig, W. A. (1986) · The Journal of Pediatrics · doi:10.1016/s0022-3476(86)80754-5 · Cited by 315 · cited 4×
“PAE refers to the persistent suppression of bacterial growth following exposure to an antimicrobial [2, 7, 10].”
InfluentialSelf-citation
Cited by
Items 301–400 of 1,003
Katsube, T., ECHOLS, R. M., Ferreira, J. C. A., Krenz, H., Berg, J. K., & Galloway, C. (2016) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.841 · Cited by 115
Schrag, S. J., Beall, B., & Dowell, S. F. (2000) · Clinical Microbiology Reviews · doi:10.1128/cmr.13.4.588-601.2000 · Cited by 115
“For such drugs, bactericidal efficacies of 85 to 100% were generally achieved if the drug concentration exceeded the MIC for at least 40% of the dosing interval ( 23 ).”
BackgroundInfluentialJamal, J.-A., Economou, C. J. P., Lipman, J., & Roberts, J. A. (2012) · Current Opinion in Critical Care · doi:10.1097/mcc.0b013e32835685ad · Cited by 96
Generic Vancomycin Products Fail In Vivo despite Being Pharmaceutical Equivalents of the Innovator
Vesga, Ó., Agudelo, M., Salazar, B., Rodríguez, C. A., & Zuluaga, A. F. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01044-09 · Cited by 114
“Fourth, while most medicines interact with the host only, antimicrobials also confront the invader organism, a dynamic triangle with numerous possibilities of biologic variation (3, 11, 17).”
BackgroundThe Role of Antibiotic Stewardship in Promoting Appropriate Antibiotic Use
Ha, D. R., Haste, N. M., & Gluckstein, D. P. (2017) · American Journal of Lifestyle Medicine · doi:10.1177/1559827617700824 · Cited by 115
Pharmacokinetic and Pharmacodynamic Profiles of Cefiderocol, a Novel Siderophore Cephalosporin
Katsube, T., ECHOLS, R. M., & Wajima, T. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz828 · Cited by 114
“Thus, an improved in vitro potency in addition to a well-characterized favorable PK/PD profile are crucial to achieve both adequate exposure to the antibiotic over the minimum inhibitory concentration (MIC) of the pathogen and clinical cure in patients infected with drug-resistant pathogens [1, 6].”
BackgroundOptimizing outcomes with antimicrobial therapy through pharmacodynamic profiling
Nicolau, D. P. (2003) · Journal of Infection and Chemotherapy · doi:10.1007/s10156-003-0279-x · Cited by 114
Brooks, I., Gooch, W. M., Jenkins, S. G., Pichichero, M. E., Reiner, S. A., Sher, L., & Yamauchi, T. (2000) · PubMed · Cited by 114
Mattioli, F., Fucile, C., Bono, V. D., Marini, V., Parisini, A., Molin, A., Zuccoli, M. L., Milano, G., Danesi, R., Marchese, A. E., et al. (2016) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-016-2053-x · Cited by 113
“Furthermore, efficacy may be anticipated by the minimum plasma concentration (Cmin) targeted to values at least four times the MIC value (Cmin > 4× MIC) [10].”
Cusumano, J. A., Klinker, K. P., Huttner, A., Luther, M. K., Roberts, J. A., & LaPlante, K. L. (2020) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/zxaa128 · Cited by 113
Ulldemolins, M., Soy, D., Llauradó‐Serra, M., Vaquer, S., Castro, P., Rodríguez, A. H., Pontes, C., Calvo, G., Torres, A., & Martín‐Loeches, I. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00712-15 · Cited by 112
“It is important to highlight that we have principally based our empirical dosing recommendations on targeting of the 100% of the ƒuT MIC rather than 40% of the ƒuT MIC described in the classical studies (3).”
BackgroundMethodExploring the role of the immune response in preventing antibiotic resistance
Handel, A., Margolis, E. B., & Levin, B. R. (2008) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2008.10.025 · Cited by 112
“Despite the general recognition of the important role of the host’s defenses, most studies of the withinhost dynamics of bacteria and antibiotics focus almost exclusively on the pharmacokinetics (PK) and the pharmacodynamics (PD) of the drug and bacteria, without explicitly considering the immune response (Lipsitch an…”
BackgroundIn vitro pharmacodynamic models to determine the effect of antibacterial drugs
Gloede, J., Scheerans, C., Derendorf, H., & Kloft, C. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp434 · Cited by 112
Delattre, I., Taccone, F., Jacobs, F., Hites, M., Dugernier, T., Spapen, H. D., Laterre, P., Wallemacq, P. E., Françoise Van Bambeke, A., & Tulkens, P. M. (2017) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2017.1338139 · Cited by 112
Hartman, S. J. F., Brüggemann, R. J. M., Orriëns, L. B., Dia, N., Schreuder, M. F., & de Wildt, S. N. (2019) · Clinical Pharmacokinetics · doi:10.1007/s40262-019-00813-w · Cited by 111
Levofloxacin Efficacy in the Treatment of Community-Acquired Legionellosis
Yu, V. L., Greenberg, R. N., Zadeikis, N., Stout, J. E., Khashab, M. M., Olson, W. H., & Tennenberg, A. M. (2004) · CHEST Journal · doi:10.1378/chest.125.6.2135 · Cited by 111
LEIBOVITZ, E., JANCO, J., PIGLANSKY, L., PRESS, J., YAGUPSKY, P., REINHART, H., YANIV, I., & DAGAN, R. (2000) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-200011000-00006 · Cited by 101
Clinical Pharmacokinetics and Pharmacodynamics of Cefepime
Pais, G. M., Chang, J. H. T., Barreto, E. F., Stitt, G. A., Downes, K. J., Al‐Shaer, M. H., Lesnicki, E., Panchal, V., Bruzzone, M., Bumanglag, A. V., et al. (2022) · Clinical Pharmacokinetics · doi:10.1007/s40262-022-01137-y · Cited by 110
“Similarly, early neutropenic murine thigh and lung infection models with Enterobacteriaceae and Klebsiella pneumoniae treated with cefotaxime demonstrated that antibacterial effects of cephalosporins were optimized when free drug concentrations in serum (f) were maintained above the MIC for 35–40% of the dosing interv…”
BackgroundBishburg, E., & Bishburg, K. (2009) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2009.06.021 · Cited by 110
Antibiotic Dosing in Multiple Organ Dysfunction Syndrome
Ulldemolins, M., Roberts, J. A., Lipman, J., & Rello, J. (2011) · CHEST Journal · doi:10.1378/chest.10-2371 · Cited by 110
Krueger, W. A., Bulitta, J. B., Kinzig‐Schippers, M., Landersdorfer, C. B., Holzgrabe, U., Naber, K. G., Drusano, G. L., & Sörgel, F. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.5.1881-1889.2005 · Cited by 110
“Considerable evidence demonstrates that the amount of time that free drug concentrations exceed the MIC is the measure of drug exposure most closely linked to the ability of a regimen of -lactam antibiotics to kill the target organisms ( 9 , 17, 19, 48).”
BackgroundInfluentialKullar, R., Leonard, S. N., Davis, S. L., Delgado, G., Pogue, J. M., Wahby, K. A., Falcione, B. A., & Rybak, M. J. (2011) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.31.5.441 · Cited by 109
Dudley, M. N., & Ambrose, P. G. (2000) · Current Opinion in Microbiology · doi:10.1016/s1369-5274(00)00132-6 · Cited by 109
Pharmacodynamics of Antimicrobials: General Concepts and Applications
Craig, W. A. (2001) · doi:10.3109/9780203908372-3 · Cited by 109
Self-citationShazely, B. E., Yu, G., Johnston, P. R., & Rolff, J. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.00103 · Cited by 108
“It is assumed that the shape of pharmacodynamic curve does not change (Craig, 1998).”
BackgroundPharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units
Roos, J. F., Bulitta, J., Lipman, J., & Kirkpatrick, C. M. J. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl349 · Cited by 101
Boucher, H. W., Ambrose, P. G., Chambers, H. F. “., Ebright, R. H., Jezek, A., Murray, B. E., Newland, J. G., Ostrowsky, B. E., Rex, J. H., & on behalf of the Infectious Diseases Society of America (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix211 · Cited by 108
“The first layer of certainty supporting the adequacy of an antimicrobial drug dosing regimen can be obtained from preclinical animal and in vitro PK/PD infection models [24, 25].”
de Velde, F., de Winter, B. C. M., Koch, B. C. P., van Gelder, T., & Mouton, J. W. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw226 · Cited by 106
VanScoy, B. D., Mendes, R. E., Nicasio, A. M., Castanheira, M., Bulik, C. C., Okusanya, Ó. O., Bhavnani, S. M., Forrest, A., Jones, R. N., Friedrich, L. V., et al. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02513-12 · Cited by 107
Frei, C. R., Wiederhold, N. P., & Burgess, D. S. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm536 · Cited by 107
Andes, D., & van Ogtrop, M. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.4.938-942.2000 · Cited by 97
“The time course of antimicrobial activity can be determined by two characteristics: (i) the effect of increasing drug concentrations on the extent of organism killing and (ii) the presence or absence of antimicrobial effects which persist after the levels in serum have fallen below the MIC (9).”
BackgroundRichter, D., Frey, O. R., Röhr, A. C., Roberts, J. A., Koeberer, A., Fuchs, T., Papadimas, N., Heinzel‐Gutenbrunner, M., Brenner, T., Lichtenstern, C., et al. (2019) · Infection · doi:10.1007/s15010-019-01352-z · Cited by 106
“CI infusion represents a reasonable approach of customized drug dosing in the ICU as to extend the time that the unbound fraction of PIP remains above the pathogen-specific minimum inhibitory concentration (MIC) (fT>MIC) [6, 7, 13, 14] up to 100% of the dosing interval [10, 12, 15].”
BackgroundAndes, D. R., Anon, J. B., Jacobs, M. R., & Craig, W. A. (2004) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2004.03.009 · Cited by 106
“The magnitude of PK/PD parameters required to produce clinically meaningful antimicrobial efficacy in susceptible organisms is not different in resistant organisms [1,5,20].”
BackgroundSelf-citationTeo, J. Q.-M., Liew, Y., Lee, W., & Kwa, A. L. (2014) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2014.01.027 · Cited by 106
Sinnollareddy, M., Roberts, M. S., Lipman, J., & Roberts, J. A. (2012) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2012.05715.x · Cited by 105
Kumar, A. (2014) · Virulence · doi:10.4161/viru.26913 · Cited by 86
“Experimental studies including murine neutropenic thigh infection and pneumonia models suggests that a fT > MIC of >40– 70% (depending on the class of β-lactam) during the course of therapy yields maximal rate of pathogen clearance and clinical response/cure rate.(197) There are relatively few studies that examine the…”
BackgroundGrace, E. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dks066 · Cited by 105
Pharmacokinetics and pharmacodynamics of meropenem in critically ill patients
Kitzes‐Cohen, R., Farin, D., Piva, G., & Myttenaere-Bursztein, S. A. D. (2002) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(01)00474-5 · Cited by 104
Guidelines for Empiric Antimicrobial Prescribing in Community-Acquired Pneumonia
File, T. M., Garau, J., Blasi, F., Chidiac, C., Klugman, K. P., Lode, H. M., Lonks, J. R., Mandell, L. A., Ramírez, J. A., & Yu, V. L. (2004) · CHEST Journal · doi:10.1378/chest.125.5.1888 · Cited by 104
Pharmacokinetic evaluation of piperacillin-tazobactam
Hayashi, Y., Roberts, J. A., Paterson, D. L., & Lipman, J. (2010) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2010.506187 · Cited by 103
“Data on the precise T> MIC required for optimal activity for b-lactam antibiotics have been obtained from dynamic in vitro and animal in vivo models and suggest that f T> MIC 50% is required for Gram-negative bacteria and 40 -- 50% for Grampositive bacteria [69,70].”
BackgroundThe Alexander Project: the benefits from a decade of surveillance
Felmingham, D., White, A. R., Jacobs, M. R., Appelbaum, P. C., Poupard, J. A., Miller, L. A., & Grüneberg, R. N. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki297 · Cited by 103
Abdulla, A., Ewoldt, T. M. J., Hunfeld, N., Muller, A. E., Rietdijk, W. J. R., Polinder, S., van Gelder, T., Endeman, H., & Koch, B. C. P. (2020) · BMC Infectious Diseases · doi:10.1186/s12879-020-4781-x · Cited by 101
DeRyke, C. A., Lee, S. Y., Kuti, J. L., & Nicolau, D. P. (2006) · Drugs · doi:10.2165/00003495-200666010-00001 · Cited by 102
Pharmacokinetics and pharmacodynamics of cefovecin in dogs
Stegemann, M. R., Sherington, J., & BLANCHFLOWER, S. E. (2006) · Journal of Veterinary Pharmacology and Therapeutics · doi:10.1111/j.1365-2885.2006.00801.x · Cited by 102
Tigecycline: a novel glycylcycline antibiotic
Zhanel, G. G., Karlowsky, J. A., Rubinstein, E., & Hoban, D. J. (2006) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.4.1.9 · Cited by 102
Limitations of Antibiotic MIC-Based PK-PD Metrics: Looking Back to Move Forward
Landersdorfer, C. B., & Nation, R. L. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.770518 · Cited by 101
“The dose fractionation is intended to enable differentiation across the three PK-PD indices, by untangling the interdependence of Cmax/MIC, AUC/MIC and %T>MIC if the same dosing interval was used for each total daily dose (Craig, 1998).”
BackgroundMethodMacVane, S. H., Kuti, J. L., & Nicolau, D. P. (2013) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2013.10.021 · Cited by 101
“non-protein-bound) f) drug exhibits pharmacological activity, therefore these paramters are commonly expressed as the ratio of the maximum free rug concentration to the MIC, the ratio of the area under the free rug concentration–time curve to the MIC and the percentage of he dosing interval that the free drug concentr…”
BackgroundPharmacodynamic effects of subinhibitory antibiotic concentrations
Odenholt, I. (2001) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(00)00243-0 · Cited by 101
In vivo pharmacodynamics of HMR 3270, a glucan synthase inhibitor, in a murine candidiasis model
Andes, D., Marchillo, K., Lowther, J., Bryskier, A., Stamstad, T., & Conklin, R. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.4.1187-1192.2003 · Cited by 100
“For drugs displaying this pattern of activity the peak/MIC ratio has most often been the pharmacokinetic/pharmacodynamic (PK/PD) parameter predictive of efficacy (4, 6, 7).”
BackgroundAfshar, N., Tabas, J. A., Afshar, K., & Silbergleit, R. (2009) · Journal of Hospital Medicine · doi:10.1002/jhm.382 · Cited by 100
Pharmacokinetics and pharmacodynamics of the new fluoroquinolones: focus on respiratory infections
Zhanel, G. G., & Noreddin, A. M. (2001) · Current Opinion in Pharmacology · doi:10.1016/s1471-4892(01)00080-7 · Cited by 100
Continuous versus intermittent infusions of antibiotics for the treatment of severe acute infections
Shiu, J. R., Wang, E., Tejani, A. M., & Wasdell, M. B. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008481.pub2 · Cited by 100
Felton, T., Hope, W. W., Lomaestro, B. M., Butterfield, J. M., Kwa, A. L., Drusano, G. L., & Lodise, T. P. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00521-12 · Cited by 100
Clinical Implications of Pharmacokinetics and Pharmacodynamics of Fluoroquinolones
Wispelwey, B. (2005) · Clinical Infectious Diseases · doi:10.1086/428053 · Cited by 100
Pharmacodynamic Optimization for Treatment of Invasive Candida auris Infection
Lepak, A. J., Zhao, M., Berkow, E. L., Lockhart, S. R., & Andes, D. R. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00791-17 · Cited by 89
“The treatment results were analyzed using a sigmoidal maximum effect (Emax) model (22).”
MethodKuti, J. L., Nightingale, C. H., & Nicolau, D. P. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.7.2464-2470.2004 · Cited by 100
“Ideal pharmacodynamic goals for each antimicrobial class have been studied and discussed in previous works (3, 6, 7, 30, 32, 33).”
BackgroundFile, T. M. (2002) · Clinical Infectious Diseases · doi:10.1086/324526 · Cited by 100
Entenza, J. M., Hohl, P., Heinze‐Krauss, I., Glauser, M. P., & Moreillon, P. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.1.171-177.2002 · Cited by 99
“otics correlate with the duration of time that the levels in serum exceed the MIC for the infecting organisms, with maximal bacteriological efficacy predictably seen when the levels in serum remain above the MIC for about 30 to 50% of the dosing interval (3, 4).”
BackgroundIn vivo pharmacodynamics of a new triazole, ravuconazole, in a murine candidiasis model
Andes, D., Marchillo, K., Stamstad, T., & Conklin, R. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.4.1193-1199.2003 · Cited by 98
“Studies with numerous antimicrobials have also shown that the magnitude of the PK/PD parameter required for efficacy is similar for drugs within the same class provided free-drug concentrations are considered and is similar in the treatment of organisms with reduced-susceptibility (2, 4).”
BackgroundKoeth, L. M., Good, C. E., Appelbaum, P. C., Goldstein, E. J. C., Rodloff, A. C., Claros, M., & Dubreuil, L. J. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh248 · Cited by 98
Optimal Use of Modern Antibiotics: Emerging Trends
Polk, R. E. (1999) · Clinical Infectious Diseases · doi:10.1086/520196 · Cited by 98
“The dynamics of bacterial response to antibiotic exposure reflect both dose and duration [48].”
BackgroundBarbot, A., Venisse, N., Rayeh, F., Bouquet, S., Debaene, B., & Mimoz, O. (2003) · Intensive Care Medicine · doi:10.1007/s00134-003-1859-z · Cited by 97
“The glycopeptides are characterized by concentrationindependent killing [19].”
BackgroundJorgensen, J. H., Crawford, S. A., & Fiebelkorn, K. R. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.7.3162-3171.2005 · Cited by 97
“However, in establishing breakpoints, it is important to take into consideration pharmacokinetic and pharmacodynamic criteria as well as existing published clinical response data with the various antimicrobial agents ( 13 , 26).”
BackgroundMavridou, E., Bruggemann, R. J. M., Melchers, W. J. G., Verweij, P. E., & Mouton, J. W. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00606-10 · Cited by 85
“For most triazoles, effect is governed only by the concentration of free drug (1, 5).”
BackgroundHaddad, N., Carr, M., Balian, S., Lannin, J., Kim, Y., Toth, C., & Jarvis, J. (2022) · Antibiotics · doi:10.3390/antibiotics11121843 · Cited by 96
“Although both pharmacokinetic parameters fT > MIC and Cmax are important in determining the therapeutic efficacy of vancomycin, the AUC/MIC ratio is the major determinant of its therapeutic efficacy [16,119].”
BackgroundInfluentialClinical Pharmacology of the Fluoroquinolones: Studies in Human Dynamic/Kinetic Models
Schentag, J. J. (2000) · Clinical Infectious Diseases · doi:10.1086/314059 · Cited by 96
“have shown pharmacokinetic-pharmacodynamic (PK-PD) relationships to correlate with bacterial killing [6-10].”
BackgroundMethodInfluentialUlldemolins, M., Vaquer, S., Llauradó‐Serra, M., Pontes, C., Calvo, G., Soy, D., & Martín‐Loeches, I. (2014) · Critical Care · doi:10.1186/cc13938 · Cited by 96
“to 60 % T>MIC for maximal bactericidal activity, cephalosporins require a 60 to 70 % T>MIC and carbapenems require a 40 % T>MIC [54].”
BackgroundButterfield, J. M., Patel, N., Pai, M. P., ROSANO, T. G., Drusano, G. L., & Lodise, T. P. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01674-10 · Cited by 96
“The past 25 years have witnessed tremendous advances in understanding the relationship between antimicrobial pharmacodynamics and microbiological response, and the pharmacodynamic targets associated with maximal effect have been identified for many antimicrobials (8, 9, 14, 16).”
BackgroundPharmacodynamics: Relation to antimicrobial resistance
Rybak, M. J. (2006) · American Journal of Infection Control · doi:10.1016/j.ajic.2006.05.227 · Cited by 96
Meropenem Pharmacokinetics in the Newborn
van den Anker, J. N., Pokorná, P., Kinzig‐Schippers, M., Martínková, J., de Groot, R., Drusano, G. L., & Sörgel, F. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00351-09 · Cited by 95
β-lactam Therapeutic Drug Management in the PICU*
Cies, J. J., Moore, W. S., Enache, A., & Chopra, A. (2017) · Critical Care Medicine · doi:10.1097/ccm.0000000000002817 · Cited by 95
Thompson, G. R., Soriano, À., Honoré, P. M., Bassetti, M., Cornely, O. A., Kollef, M. H., Kullberg, B. J., Pullman, J. R., Hites, M., Fortün, J., et al. (2023) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(23)00551-0 · Cited by 94
Cassetta, M. I., Marzo, T., Fallani, S., Novelli, A., & Luigi Messori, A. (2014) · BioMetals · doi:10.1007/s10534-014-9743-6 · Cited by 94
“Notably, such a method may give specific insight on the pharmacodynamic properties of the different drugs regarding either their concentration-or time-dependent activity (Craig 1998).”
MethodExtracellular concentrations of fosfomycin in lung tissue of septic patients
Matzi, V., Lindenmann, J., Porubsky, C., Kugler, S. A., Maier, A., Dittrich, P., Smolle-Jüttner, F.-M., & Joukhadar, C. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq070 · Cited by 94
Acute Community-Acquired Bacterial Sinusitis: Continuing Challenges and Current Management
Sande, M. A., & Gwaltney, J. M. (2004) · Clinical Infectious Diseases · doi:10.1086/421353 · Cited by 94
“the MIC90 for the pathogen [31, 35, 36].”
Treatment of drug-resistant pneumococcal pneumonia
Garau, J. (2002) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(02)00316-x · Cited by 94
Lepak, A. J., Marchillo, K., VanHecker, J., & Andes, D. R. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01355-13 · Cited by 88
Özgün, H., Ertuğrul, B., Soyder, A., Öztürk, B., & Aydemir, M. (2009) · International Journal of Surgery · doi:10.1016/j.ijsu.2009.12.005 · Cited by 93
Felton, T., Roberts, J. A., Lodise, T. P., Guilder, M. V., Boselli, E., Neely, M. N., & Hope, W. W. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02664-14 · Cited by 93
“MIC ) is the pharmacodynamic index that best links drug exposure with the antibacterial effect (10).”
BackgroundWalker, R. (2000) · Australian Veterinary Journal · doi:10.1111/j.1751-0813.2000.tb10528.x · Cited by 93
Wagenlehner, F., Kinzig‐Schippers, M., Sörgel, F., Weidner, W., & Naber, K. G. (2006) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2006.07.026 · Cited by 93
“AUC/MIC ratios as well s peak concentration/MIC ratios have been used to describe uoroquinolone pharmacodynamics [9,14–16].”
BackgroundMethodInfluentialCraig, W. A., & Andes, D. R. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01273-07 · Cited by 93
“The neutropenic mouse thigh infection model has been used extensively and has facilitated the quantitative determination of PK-PD indices useful for the prediction of antibiotic efficacy in patients ( 9 ).”
MethodSelf-citationPharmacodynamic Thresholds for Beta-Lactam Antibiotics: A Story of Mouse Versus Man
Berry, A. V., & Kuti, J. L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.833189 · Cited by 92
“Against Gram-negative and many Gram-positive bacteria, cephalosporin based beta-lactams typically required 60–70% fT > MIC for 1–2 log10 CFU reductions and 30–40% fT > MIC for stasis (e.g., cefotaxime against Klebsiella pneumoniae in the neutropenic murine lung infection model) (Craig, 1998).”
BackgroundDownes, K. J., Hahn, A., Wiles, J. R., Courter, J. D., & Vinks, A. A. T. M. M. (2013) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2013.11.006 · Cited by 92
“Linezolid exhibits bacteriostatic activity against Gram-positive organisms such as staphylococci and enterococci and has time-dependent killing with moderate PAEs, which are increased at higher concentrations relative to the MIC of the organism [68].”
BackgroundInfluentialCiofu, O., Mandsberg, L. F., Wang, H., & Høiby, N. (2012) · FEMS Immunology & Medical Microbiology · doi:10.1111/j.1574-695x.2012.00983.x · Cited by 92
“Dosage optimization based on the pharmacokinetics (PK) and pharmacodynamics (PD) of antimicrobial agents is extremely important to maximize the effect of antibiotics at the infection site and to prevent further development of antimicrobial resistance (Craig, 1998; Safdar et al., 2004).”
BackgroundPlasma and tissue pharmacokinetics of cefpirome in patients with sepsis
Joukhadar, C., Klein, N., Mayer, B. X., Kreischitz, N., Delle‐Karth, G., Palkovits, P., Heinz, G., & Müller, M. (2002) · Critical Care Medicine · doi:10.1097/00003246-200207000-00013 · Cited by 92
“High bacterial killing can be expected from the first antibiotic dosage when the pathogen’s MIC-value is covered for at least 60% to 70% of the dosing interval (15).”
BackgroundTreatment of acute otitis media — challenges in the era of antibiotic resistance
Dagan, R. (2000) · Vaccine · doi:10.1016/s0264-410x(00)00272-3 · Cited by 92
A Review of New Fluoroquinolones: Focus on their Use in Respiratory Tract Infections
Zhanel, G. G., Fontaine, S., Adam, H. J., Schurek, K. N., Mayer, M. L., Noreddin, A. M., Gin, A. S., Rubinstein, E., & Hoban, D. J. (2006) · Treatments in Respiratory Medicine · doi:10.2165/00151829-200605060-00009 · Cited by 91
Cantón, R., Cobos, N., de Gracia, J., Baquero, F., Honorato, J., Gärtner, S., Álvarez, A., Salcedo, A., Oliver, A., & Garcia-Quetglas, E. (2005) · Archivos de Bronconeumología · doi:10.1016/s0300-2896(05)70731-6 · Cited by 91
“En este caso, cuando el cociente C máx /CMI es superior a 10 se asocia con porcentajes elevados de muerte bacteriana, curación clínica y prevención de desarrollo de resistencias [141] [142] [143] [144] .”
BackgroundLortholary, O., Lefort, A., Tod, M. M., Chomat, A. M., Darras-Joly, C., & Cordonnier, C. (2008) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(08)70228-7 · Cited by 91
Katsube, T., Wajima, T., Ishibashi, T., Ferreira, J. C. A., & ECHOLS, R. M. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01381-16 · Cited by 91
Udy, A. A., Roberts, J. A., Waele, J. J. D., Paterson, D. L., & Lipman, J. (2012) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2012.02.010 · Cited by 91
“Successful application of antibiotic therapy in the critically ill equires not only timely administration of an agent of approprite spectrum but the provision of adequate drug concentrations t the site of infection [1].”
BackgroundNguyen, H. M., Shier, K. L., & Graber, C. J. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt450 · Cited by 90
Optimizing Antimicrobial Drug Dosing in Critically Ill Patients
Póvoa, P. M. S. R., Moniz, P., Gonçalves-Pereira, J., & Coelho, L. (2021) · Microorganisms · doi:10.3390/microorganisms9071401 · Cited by 91
“These PK parameters, along with respective dosage strategies and physicochemical characteristics, will determine serum drug concentrations and consequently the concentration in body fluids and tissues [10].”
BackgroundInfluentialWolff, M., Joly‐Guillou, M., Farinotti, R., & Carbon, C. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.6.1406 · Cited by 90
“This finding is in accordance with previous experimental data (6).”
ResultImpact of Burden on Granulocyte Clearance of Bacteria in a Mouse Thigh Infection Model
Drusano, G. L., Fregeau, C., Liu, W., Brown, D. L., & Louie, A. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00133-10 · Cited by 90
“While the scientific community has developed extensive literature corresponding to many animal model systems in which the ability of an antibiotic to kill bacteria at the primary infection site has been linked to drug exposure (2, 4, 11, 12), little has been done to examine this issue in vivo relative to the granulocy…”
BackgroundClinical pharmacodynamics of quinolones
Ambrose, P. G., Bhavnani, S. M., & Owens, R. C. (2003) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(03)00061-8 · Cited by 89
Re-evaluating current antibiotic therapy
Craig, W. A. (2001) · Respiratory Medicine · doi:10.1016/s0954-6111(01)90023-x · Cited by 90
“This may be due to the much longer in vivo PAEs produced by azithromycin, in comparison with other macrolides or fl-lactams (2).”
InfluentialSelf-citationDalhoff, A., Ambrose, P. G., & Mouton, J. W. (2009) · Infection · doi:10.1007/s15010-009-7108-9 · Cited by 89
“Antimicrobial agents can be categorized by the best fit between these composite parameters (i.e., AUC/MIC, Cmax/MIC, T > MIC) and their efficacy [43, 44 ].”
BackgroundPharmacokinetics of Cefepime during Continuous Renal Replacement Therapy in Critically Ill Patients
Malone, R. S., Fish, D. N., Abraham, E., & Teitelbaum, I. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.11.3148-3155.2001 · Cited by 89
“Additional studies have also suggested that both AUC0–24/ MIC and T MIC are important predictors of clinical efficacy and the risk of the development of microbial resistance (10, 30).”
BackgroundInfluential
Metadata
- Authors
- Craig, W. A.
- Affiliations
- William S. Middleton Memorial Veterans Hospital (US)
- Corresponding author
- Craig, William A.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 1998-01
- Volume
- 26
- Issue
- 1
- Pages
- 1-10
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2113717321
- Cited by
- 2,908
- References
- 50
- Citations by year
- 2026: 68 · 2025: 81 · 2024: 82 · 2023: 99 · 2022: 86 · 2021: 89 · 2020: 103 · 2019: 94 · 2018: 105 · 2017: 124 · 2016: 136 · 2015: 113 · 2014: 129 · 2013: 109 · 2012: 101
- FWCI
- 54.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Keywords
- pharmacokinetics/pharmacodynamics, dosing regimen, pharmacodynamic parameters, pharmacokinetic parameters, animal models of infection, human infection, susceptibility breakpoints, antimicrobial resistance, emerging pathogens, drug development costs
- MeSH terms
- Animals, Anti-Bacterial Agents, Bacteria, Humans, Lactams, Microbial Sensitivity Tests, Fluoroquinolones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.